[Secondary hypertension: diagnosis and treatment]

Paolo Verdecchia1, Gianpaolo Reboldi2, Giovanni Mazzotta3

  • 1Fondazione Umbra Cuore e Ipertensione-ONLUS, Perugia - S.C. Cardiologia, Ospedale S. Maria della Misericordia, Perugia.

Giornale Italiano Di Cardiologia (2006)
|September 6, 2024
PubMed

Insights

Secondary hypertension, often overlooked, affects 5-10% of patients and is more common in difficult-to-control cases. Suspect secondary causes in young patients, those with resistant hypertension, or specific clinical signs.

Area of Science:

  • Cardiology
  • Endocrinology
  • Nephrology

Background:

  • Essential hypertension lacks clear causes in most patients.
  • Secondary hypertension, due to identifiable causes, is found in 5-10% of hypertensive individuals, rising to over 20% in resistant cases.
  • Recognizing secondary hypertension is crucial for effective management.

Purpose of the Study:

  • To review the causes, prevalence, and diagnostic clues of secondary hypertension.
  • To highlight specific conditions associated with secondary hypertension across different age groups.
  • To provide guidance on when to suspect and investigate secondary hypertension.

Main Methods:

  • Literature review of secondary hypertension causes and prevalence.
  • Analysis of clinical characteristics and diagnostic indicators.
  • Categorization of causes by age group (children, adults, elderly).

Main Results:

  • Secondary hypertension prevalence increases significantly in treatment-resistant cases.
  • Common causes vary by age: aortic conditions in children; renal artery stenosis, primary hyperaldosteronism, Cushing's in adults.
  • Parenchymal nephropathy and hyperparathyroidism occur at all ages; pheochromocytoma/paraganglioma in younger adults.
  • Key suspicion indicators include early onset (<30 years), treatment resistance, severe or rapidly worsening hypertension, endocrine signs, non-dipping BP, and sleep apnea.

Conclusions:

  • Secondary hypertension is a significant contributor to difficult-to-control blood pressure.
  • A high index of suspicion and targeted investigation are necessary for diagnosis.
  • Identifying and treating secondary causes can lead to improved hypertension management and outcomes.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.0K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
158
Alterations in Blood Pressure01:30

Alterations in Blood Pressure

Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
1.2K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
142
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
136